CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

SOCIALIST REPUBLIC OF VIETNAM Independence – Freedom – Happiness

No.: \ /CV-DPTU2

Hanoi, date / March 2025

To:

- The State Securities Commission of Vietnam
- Hanoi Stock Exchange

Central Pharmaceutical Joint Stock Company No2 (Stock code: **DP2**) respectfully extends our greetings and sincere appreciation for your continued attention and support.

Implementing Circular No. 96/2020/TT-BTC dated November 16th, 2020, issued by the Ministry of Finance, providing guidance on information disclosure in the securities market;

1. Explanation regarding the Auditor's disclaimer of opinion in the reviewed Financial Statements as follows:

In the Independent Audit Report No.2603.01-25/BC-TC/VAE issued by Viet Nam Auditing & Evaluation Company Limited on ____ March 2025, a disclaimer of opinion was expressed as of December 31st, 2024, concerning the following matters:

In the audit report on the Financial Statements for the fiscal year ended December 31st, 2023, we have issued a disclaimer of opinion because the Company recognized an increase in other income from the amount received as support under the Agreement Minutes on Share Transfer of Binh An Developed Investment Joint Stock Company from the Company to Dat Viet Financial Investment Joint Stock Company to determine business results for the years from 2010 to 2016, with a value of VND 99,600,000,000. As of the date of issuance of this report, we have not been provided with documents and records related to the completion of the share transfer procedures mentioned above. Therefore, we are unable to assess the impact of this matter on the Company's Financial Statements for the fiscal years ended December 31st, 2024 and December 31st, 2023.

We have not been provided with the Financial Statements for the fiscal years ended December 31st, 2024 and December 31st, 2023, of Binh An Developed Investment Joint Stock Company as a basis for considering the provision for investment loss (if any). Therefore, we cannot assess the impact of the aforementioned matter on the Company's Financial Statements for the fiscal years ended December 31st, 2024 and December 31st, 2023.

DP2 provides the following explanation regarding the Auditing Company's disclaimer of opinion:

Since the project "Commercial Service Complex on land area No. 9 Tran Thanh Tong" has not yet commenced operations, Central Pharmaceutical Joint Stock Company No2 has not completed the share transfer procedures to Dat Viet Financial Investment Joint Stock Company.

According to Investment Cooperation Contract No. 01/HTDT dated December 28, 2007, between Central Pharmaceutical Joint Stock Company No2 and Dat Viet Financial Investment Joint Stock Company for the establishment of Binh An Investment and Development Joint Stock Company to implement the project "Commercial Service Complex on land area No. 9 Tran Thanh Tong." Currently, as the project has not yet commenced operations, Binh An Investment and Development Joint Stock Company has not generated any economic transactions.

2. Explanation of business losses in the financial statements 2024:

In the financial statements 2024 dated March 24th, 2023, of Central Pharmaceutical Joint Stock Company No2, the net profit after tax in 2023 was: (negative) VND -24,049,332,369, and in 2024 was: (negative) VND -5,554,108,995, a decrease in loss by 76.9% compared to the previous year.

DP2 provides the following explanation for the loss in business operations:

In 2024, the Company has increased its production and business activities, restructured its product line, and continuously sought solutions to improve labor productivity, reduce costs, minimize defects, and decrease losses during the production process. Additionally, the company received a reduction in penalty interest rates from the bank, which led to a decrease in interest expenses. As a result, the loss has reduced compared to the previous year.



3. Explanation of the difference between the pre- and post-audit profit:

In the financial statements of 4th Quarter 2024 of Central Pharmaceutical Joint Stock Company No2, the net profit after tax before the audit was: (negative) VND -5,222,175,635, and after the audit was: (negative) VND -5,554,108,995. (The difference in net profit in the reporting period before and after the audit is 5.98%).

DP2 provides the following explanation for the difference:

The company added a provision for doubtful receivables.

DP2 kindly requests the assistance of your esteemed agency.

Sincerely!

Recipients:

- As above;

- Archives Office, Accounting Finance

GENERAL DIRECTOR

CÔNG TY CỔ PHẨN DƯỢC PHẨM TRUNG ƯƠNG 2

TRUNG Le Tien Dung

